Antimicrobial resistance: time for action
MetadataMostrar registro completo
The year 2020 will be remembered for the SARS-CoV-2 coronavirus pandemic, responsible for more than 10 million cases and more than 500 000 deaths in the first half of the year alone, and receiving unprecedented political and social attention. This global public health crisis should draw attention to other silent epidemics, such as antimicrobial resistance (AMR), responsible for 700 000 annual deaths worldwide, 230 000 of them from multi-drug-resistant tuberculosis.2 In the Region of the Americas, multidrug-resistant microorganisms are the leading cause of health care-associated infections. Surveillance data from the Latin American Network for Antimicrobial Resistance Surveillance (RELAVRA) show an increasing trend in the resistance of hospital pathogens such as Klebsiella pneumoniae, whose non-susceptibility to carbapenem antibiotics has been increasing significantly in Latin America since 2014, reaching an average of 21%.3 There are significant consequences for health systems in terms of mortality, disability, and economic costs. For example, Staphylococcus aureus causes a wide range of infections and is one of the most commonly isolated microorganisms in health care-associated infections; in Latin America, more than 25% of S. aureus isolates are resistant to methicillin. The result is 45.2% excess mortality attributable to methicillin resistance, compared to susceptible strains, and increased antibiotic treatment costs (6.7 times greater) and hospitalization (almost 3 times greater).
Da Silva Jr. JB, Espinal M, Ramón-Pardo P. Antimicrobial resistance: time for action. Rev Panam Salud Publica. 2020;44:e131. https://doi.org/10.26633/RPSP.2020.131
Este aviso deve ser preservado juntamente com o URL original do artigo.Attribution-NonCommercial-ShareAlike 3.0 IGO
Apresentado os itens relacionados pelo título, autor e assunto.
Recommendations for Implementing Antimicrobial Stewardship Programs in Latin America and the Caribbean: Manual for Public Health Decision-Makers Pan American Health Organization; Florida International University (PAHOUnited StatesWashington, D.C., 2018)As a public good, antimicrobial medicines require rational use if their effectiveness is to be preserved. However, up to 50% of antibiotic use is inappropriate, adding considerable costs to patient care, and increasing ...
Epidemiological Alert: Emergence and increase of new combinations of carbapenemases in Enterobacterales in Latin America and the Caribbean (22 October 2021) Pan American Health Organization; Health Emergencies (PHE) (PAHOUnited StatesWashington, D.C., 2021)Given the change in the geographic distribution of carbapenemases and the emergence and dissemination of bacteria that produce more than one of these enzymes, the Pan American Health Organization / World Health Organization ...
Socioeconomic factors associated with antimicrobial resistance of Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli in Chilean hospitals (2008–2017) Allel, Kasim; García, Patricia; Labarca, Jaime; Munita, José M.; Rendic, Magdalena; Undurraga, Eduardo A.; Grupo Colaborativo de Resistencia Bacteriana (2020-09-23)[ABSTRACT]. Objective. To identify socioeconomic factors associated with antimicrobial resistance of Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli in Chilean hospitals (2008–2017). Methods. We reviewed ...